Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool January 3, 2012 Rich Smith	2012 Preview: General Electric In General Electric's case could 2012 be any worse than 2011?
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool December 18, 2008 Rich Smith	Best Stock for 2009: General Electric You still have time to board the GE train for a ride to riches in 2009.
The Motley Fool May 24, 2011 Rich Smith	Gorgeous, Generous General Electric Dividend seekers: Prepare to gorge on this opportunity.
The Motley Fool September 12, 2011 Rich Smith	General Electric vs. the World Or at least versus the S&P 500.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool November 22, 2005 Stephen D. Simpson	Diving Into The Dow: The Fifth Five The authors banter about the relative merits and investment opportunities of some the biggest companies in America: McDonald's... Merck... Microsoft... Pfizer... Procter & Gamble...
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool December 31, 2007 Dan Caplinger	Best Stock for 2008: General Electric It's not just a blue chip for widows and orphans. Energy may be the catalyst to draw investors' attention, but a closer look shows that GE is also getting the rest of its business segments firing on all cylinders.
The Motley Fool November 7, 2011 Tamara Rutter	It Pays to Invest Like a Dog Find out how the Dow's best dividend stocks can work for you.
The Motley Fool December 13, 2011 Rich Smith	GE: Getting More Gorgeous by the Day Last week's dividend hike wasn't the first, and won't be the last.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool July 18, 2007 Ryan Fuhrmann	Pfizer Prepares for L-Day Will Pfizer be able to offset the looming loss of Lipitor? Investors, take note.
The Motley Fool October 11, 2004 Roger Nusbaum	Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future.
The Motley Fool June 11, 2008 Brian Orelli	Dueling Fools: Pfizer Bull The bullish opinion on Pfizer is that this may be the best time to buy this stock.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool February 27, 2009 Alex Dumortier	GE's Dividend Head-Fake General Electric CEO Jeffrey Immelt announces that the company will cut its dividend by two-thirds, a move that will produce significant cash savings and also be a gesture of goodwill toward the credit rating agencies that are reviewing GE's rating.
The Motley Fool September 30, 2011 Abantika Chatterjee	GE Is Regaining Ground GE is out of the blues and rebuilding itself for the long run.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool January 20, 2006 Nathan Parmelee	GE Has Staying Power The market isn't happy with GE's fourth-quarter revenues, but the company is in fine shape.
The Motley Fool January 13, 2005 Selena Maranjian	Big Dividend Payers Big dividend payers can reward you well, but select carefully.
The Motley Fool July 22, 2011 Eric Dutram	Friday's ETF to Watch: Vanguard Industrials ETF Although concerns remain over debt issues, corporate profits have come in pretty strong over the past few days, making the Vanguard Industrials ETF a fund to watch.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
The Motley Fool January 10, 2012 Sean Williams	2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair.
AskMen.com Terence Channon	Recession Proof Investments Consider these recession-proof investments to make the most of a slow economic time.
The Motley Fool October 20, 2008 Brian Orelli	Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma.
The Motley Fool August 13, 2010 Ilan Moscovitz	Merck: Dividend Dynamo or Disaster? Just how safe is this dividend?
The Motley Fool January 9, 2007 Selena Maranjian	How to Earn a 3,017% Return In exchange for his $35 investment in each share of Pfizer stock 47 years ago, this 98-year-old is now receiving $1,056 per share each year. That's some payback, eh?
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool October 25, 2005 Selena Maranjian	Is Biggest Best? Even giant companies can be volatile. Don't be complacent with blue chips. It's never smart to look at just one factor for any company. To have the best chance of doing well, you need to study a company closely, evaluating its health and prospects from many angles.
The Motley Fool December 12, 2008 Rich Smith	This Just In: Upgrades and Downgrades Soleil Securities hands out "buy" ratings to Sepracor, Cephalon, Endo Pharm, and Pfizer.
The Motley Fool August 29, 2008 Brian Orelli	Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up.
The Motley Fool June 15, 2006 Selena Maranjian	My Dividends Are Bigger Than Yours Your yield may be 2% when mine is a whopping 13%. Here's the secret.
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool October 24, 2011 Sean Williams	There's More to GE's Earnings Than Meets the Eye Wall Street didn't like the earnings report, but one analyst sure did.
The Motley Fool December 19, 2005 Rick Aristotle Munarriz	4 Companies That Took a Hike Companies with growing yields can make you rich in more ways than the obvious: General Mills... Microsoft... Pfizer... T. Rowe Price...
The Motley Fool July 27, 2011 Katie Spence	Irrational Fear Has Made This Stock Cheap, but Not for Long Congress may be increasing anxiety over the economy, but GE company is poised to make it through regardless.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool November 10, 2010 Selena Maranjian	Get Your Big Yields the Right Way Some "income funds" offer less income than you'd think.